Analytical Data
-
基因名
PRAMEF2
- Application
-
别名
PRAMEF2; PRAME family member 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O60811
-
表达区间
1-474 aa
-
氨基酸序列
MSIQAPPRLL ELAGQSLLRD QALSISAMEE LPRVLYLPLF REAFSRRHFQ TLTVMVQAWP FTCLPLVSLM KTLHLEPLKA LLEGLHMLLT QKDRPRRWKL QVLDLRDVDE NFWARWPGAW ALSCFPEAMS KRQTAEDCPR TGEHQPLKVF IDICLKEIPQ DECLRYLFQW VYQRRGLVHL CCSKLVNYLT PIKYLRKSLK IIYINSIGEL EIHNTCWPHL IRKLYCYLKE MKTLCKLVFS RCHHYTSDNE LEGWLVTRFT SVFLRLEHLQ LLKIKLITFF SGHLEQLIRC LQNPLENLEL TCGNLLEEDL KCLSQFPSLG YLKHLNLSYV LLFRISLEPL GALLEKIAAS LETLVLEGCQ IHYSQLSAIL PGLSCCSQLT TFYFGSNCMS IDALKDLLRH TSGLSKLSLE TYPAPEESLN SLVRVNWEIF TPLRAELMCT LREFRQPKRI FIGPTPCPSC GSSPSEELEL HLCC
-
分子量
54.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PRAMEF2, or PRAME Family Member 2, is a gene that belongs to a family of cancer/testis (CT) antigens, which are typically expressed in testicular germ cells and various tumors but not in normal somatic tissues. This characteristic makes PRAMEF2 a potential target for cancer immunotherapy, as it could elicit specific immune responses against tumor cells while sparing normal tissues. Recent studies have highlighted the role of PRAMEF2 in promoting tumor progression by influencing cell proliferation and survival, thereby making it a candidate for further investigation in cancer biology. Understanding the mechanism of PRAMEF2 expression and its functional implications could pave the way for developing novel diagnostic and therapeutic strategies. Researchers are focused on investigating the expression profile of PRAMEF2 in different cancer types and exploring its interaction with immune cells, as this could help in designing vaccines or engineered T cells that target PRAMEF2-expressing tumors. As the field of targeted cancer immunotherapy evolves, elucidating the role of PRAMEF2 in tumor immunogenicity and its potential as a biomarker for cancer diagnosis and prognosis will be crucial for advancing personalized treatment approaches.
